JP2008535898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535898A5 JP2008535898A5 JP2008505954A JP2008505954A JP2008535898A5 JP 2008535898 A5 JP2008535898 A5 JP 2008535898A5 JP 2008505954 A JP2008505954 A JP 2008505954A JP 2008505954 A JP2008505954 A JP 2008505954A JP 2008535898 A5 JP2008535898 A5 JP 2008535898A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- compound according
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 65
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- -1 n- butoxymethyl Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 101150116411 AGTR2 gene Proteins 0.000 claims 4
- 201000006549 dyspepsia Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000008484 agonism Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101150059573 AGTR1 gene Proteins 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 206010002659 Anovulatory cycle Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000007654 ischemic lesion Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 206010038464 renal hypertension Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67025105P | 2005-04-12 | 2005-04-12 | |
| US60/670,251 | 2005-04-12 | ||
| PCT/GB2006/001319 WO2006109048A1 (en) | 2005-04-12 | 2006-04-12 | New tricyclic angiotensin ii agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012253304A Division JP5718301B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535898A JP2008535898A (ja) | 2008-09-04 |
| JP2008535898A5 true JP2008535898A5 (https=) | 2009-05-14 |
| JP5202301B2 JP5202301B2 (ja) | 2013-06-05 |
Family
ID=36616540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505954A Expired - Fee Related JP5202301B2 (ja) | 2005-04-12 | 2006-04-12 | 新規な三環系アンジオテンシンｉｉアゴニスト |
| JP2012253304A Expired - Fee Related JP5718301B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012253304A Expired - Fee Related JP5718301B2 (ja) | 2005-04-12 | 2012-11-19 | 新規な三環系アンジオテンシンｉｉアゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8080571B2 (https=) |
| EP (1) | EP1869023B1 (https=) |
| JP (2) | JP5202301B2 (https=) |
| KR (1) | KR101429484B1 (https=) |
| CN (1) | CN101193886B (https=) |
| AT (1) | ATE540947T1 (https=) |
| AU (1) | AU2006235698B2 (https=) |
| CA (1) | CA2604797C (https=) |
| DK (1) | DK1869023T3 (https=) |
| ES (1) | ES2395194T3 (https=) |
| MX (1) | MX2007012634A (https=) |
| WO (1) | WO2006109048A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| TW200840566A (en) * | 2006-12-22 | 2008-10-16 | Esteve Labor Dr | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| EP1935886A1 (en) * | 2006-12-22 | 2008-06-25 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
| EP3820498A1 (en) | 2018-06-14 | 2021-05-19 | University College Cork-National University of Ireland Cork | Peptide for disease treatment |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| KR20230004501A (ko) * | 2020-03-19 | 2023-01-06 | 바이코어 파마 아베 | 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물 |
| GB202007122D0 (en) * | 2020-05-14 | 2020-07-01 | Vicore Pharma Ab | New process |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| CA3247073A1 (en) * | 2022-04-06 | 2025-02-03 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | AT2R AGONIST |
| CN116355025B (zh) * | 2023-04-03 | 2025-03-28 | 天津医科大学 | 一种HO-1i-Pt(IV)配合物和自组装纳米粒的制备方法及其在肿瘤药物中的应用 |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| TW202508554A (zh) * | 2023-08-25 | 2025-03-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 一種作為ａｔ２ｒ促效劑的噻吩磺醯基氨基甲酸酯及其用途 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
| WO2025252142A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏柯菲平医药股份有限公司 | 一种血管紧张素ii型2受体激动剂及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
| EP0424317A3 (en) * | 1989-10-19 | 1991-09-25 | Ciba-Geigy Ag | Pyrimidines |
| DE4023215A1 (de) | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
| DE4032522A1 (de) * | 1990-10-11 | 1992-04-16 | Schering Ag | Neue thienoimidazolderivate, verfahren zu ihrer herstellung und ihre phamazeutische verwendung |
| IE920175A1 (en) | 1991-02-11 | 1992-08-12 | Zeneca Ltd | Nitrogen heterocycles |
| US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| CA2115990A1 (en) * | 1991-08-19 | 1993-03-04 | George Albert Boswell | Angiotensin ii receptor blocking imidazolinone derivatives |
| WO1993004045A1 (en) | 1991-08-19 | 1993-03-04 | E.I. Du Pont De Nemours And Company | Angiotensin ii receptor blocking imidazolinone derivatives |
| US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| GB9223371D0 (en) | 1992-11-06 | 1992-12-23 | Ici Plc | Heterocyclic compounds |
| US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| US5444067A (en) * | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| EP0882699A4 (en) * | 1996-08-06 | 2001-03-21 | Taisho Pharmaceutical Co Ltd | AMINO CONNECTIONS AND ANGIOTENSIN IV RECEPTOR AGONISTS |
| EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| DE10112041A1 (de) * | 2001-03-14 | 2002-09-26 | Aventis Pharma Gmbh | p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CA2449150C (en) * | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| WO2003064414A1 (en) * | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| JP4385113B2 (ja) * | 2002-09-18 | 2009-12-16 | 株式会社ポーラファルマ | 新規ビフェニルイミダゾピリジン誘導体及びそれを有効成分とする医薬 |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2003286251A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New bicyclic angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| MXPA05008142A (es) * | 2003-01-31 | 2005-09-30 | Sankyo Co | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension. |
| AU2003219291A1 (en) | 2003-03-24 | 2004-10-18 | Vicore Pharma Ab | Bicyclic compounds useful as angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
-
2006
- 2006-04-12 AU AU2006235698A patent/AU2006235698B2/en not_active Ceased
- 2006-04-12 CN CN200680020921.8A patent/CN101193886B/zh not_active Expired - Fee Related
- 2006-04-12 JP JP2008505954A patent/JP5202301B2/ja not_active Expired - Fee Related
- 2006-04-12 DK DK06726719.5T patent/DK1869023T3/da active
- 2006-04-12 MX MX2007012634A patent/MX2007012634A/es active IP Right Grant
- 2006-04-12 EP EP06726719A patent/EP1869023B1/en not_active Expired - Lifetime
- 2006-04-12 WO PCT/GB2006/001319 patent/WO2006109048A1/en not_active Ceased
- 2006-04-12 CA CA2604797A patent/CA2604797C/en not_active Expired - Fee Related
- 2006-04-12 ES ES06726719T patent/ES2395194T3/es not_active Expired - Lifetime
- 2006-04-12 KR KR1020077025440A patent/KR101429484B1/ko not_active Expired - Fee Related
- 2006-04-12 US US11/918,240 patent/US8080571B2/en not_active Expired - Fee Related
- 2006-04-12 AT AT06726719T patent/ATE540947T1/de active
-
2012
- 2012-11-19 JP JP2012253304A patent/JP5718301B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535899A5 (https=) | ||
| JP2008535898A5 (https=) | ||
| CN107072985B (zh) | 治疗性抑制化合物 | |
| JP5625029B2 (ja) | 新規な三環系アンジオテンシンｉｉアゴニスト | |
| TWI287545B (en) | New pyridazin-3(2h)-one derivatives | |
| WO2012102297A1 (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
| JP2015178457A (ja) | ピラゾロピリジン誘導体、またはその薬理学的に許容される塩 | |
| JP5718301B2 (ja) | 新規な三環系アンジオテンシンｉｉアゴニスト | |
| JP2016519165A (ja) | Ｗｎｔ経路モジュレーターとしてのプリンジオン | |
| EP3704113A1 (en) | Bridged bicyclic compounds as farnesoid x receptor modulators | |
| TW201113288A (en) | Inhibitors of protein tyrosine kinase activity | |
| WO2016040449A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| JP2015178458A (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| CN107056755B (zh) | 五元杂环酰胺类wnt通路抑制剂 | |
| KR20190129034A (ko) | 금속효소 억제제 화합물 | |
| WO2011095057A1 (zh) | 苯并咪唑衍生物及其药物组合物和应用 | |
| WO2017156181A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| JP4007743B2 (ja) | 血管新生阻害剤 | |
| CN113121527B (zh) | 三环类化合物及其用途 | |
| JP2008515980A (ja) | 閉塞性動脈疾患のためのアリールスルホンアミドぺリ置換二環式化合物 | |
| CN105612150B (zh) | 磺酰吲哚衍生物和制备该磺酰吲哚衍生物的方法 | |
| JP2008535900A5 (https=) | ||
| TWI909603B (zh) | 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物 | |
| WO2019142053A2 (en) | Therapeutic inhibitory compounds | |
| NZ298853A (en) | 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives |